Avigen to Present at BIO 2007 International Convention

Alameda, California, UNITED STATES


ALAMEDA, Calif., May 1, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, announced today that Chief Business Officer Michael Coffee will present information on Avigen's 2007 development programs and product pipeline at the annual BIO International Convention in Boston. Mr. Coffee will be participating in the Business Forum, and will present on Tuesday, May 8, 2007, from 2:45 to 3:00 p.m. EDT in Room D, Level One, of the Boston Convention & Exhibition Center.

About Avigen

Avigen is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company committed to its small molecule and biologics neurology products. The company currently has in development AV650 for neuromuscular spasm and spasticity and AV411 for neuropathic pain. Additionally, the company has in development a compound for the treatment of hemophilia A and B, AV513. For more information about Avigen, consult the company's website at http://www.avigen.com.

The Avigen, Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2981

Statement under the Private Securities Litigation Reform Act

This press release contains forward-looking statements, which include, among others, statements relating to Avigen's intention of completing the requirements of clinical development for each of the candidates in its product pipeline; looking for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing; and becoming a fully integrated commercial biopharmaceutical company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include those detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's Annual Report on Form 10-K for the period ended December 31, 2006, under the caption "Risk Factors" in Item 1 of Part 1A of that report, which was filed with the SEC on March 16, 2007.



        

Contact Data